VYNE Therapeutics (NASDAQ:VYNE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of VYNE Therapeutics (NASDAQ:VYNE) to a sell rating in a report issued on Saturday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of VYNE Therapeutics in a report on Wednesday, October 8th. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $4.50.

VYNE Therapeutics Price Performance

NASDAQ VYNE opened at $0.58 on Friday. VYNE Therapeutics has a 12 month low of $0.28 and a 12 month high of $4.30. The firm has a market capitalization of $19.17 million, a PE ratio of -0.74 and a beta of 1.99. The company’s 50 day simple moving average is $0.38 and its 200 day simple moving average is $0.59.

VYNE Therapeutics (NASDAQ:VYNE) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.02. The company had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.13 million. VYNE Therapeutics had a negative return on equity of 80.84% and a negative net margin of 6,425.19%. Sell-side analysts anticipate that VYNE Therapeutics will post -0.97 earnings per share for the current fiscal year.

Institutional Trading of VYNE Therapeutics

A number of hedge funds have recently bought and sold shares of VYNE. Velan Capital Investment Management LP purchased a new position in shares of VYNE Therapeutics in the second quarter worth approximately $50,000. Two Sigma Investments LP acquired a new position in VYNE Therapeutics in the 3rd quarter worth approximately $74,000. ADAR1 Capital Management LLC purchased a new position in VYNE Therapeutics during the 1st quarter worth approximately $111,000. Shay Capital LLC acquired a new stake in VYNE Therapeutics during the 3rd quarter valued at $165,000. Finally, Boothbay Fund Management LLC purchased a new stake in shares of VYNE Therapeutics in the second quarter valued at $176,000. 83.78% of the stock is owned by hedge funds and other institutional investors.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.